Last reviewed · How we verify
NPB-01
NPB-01 is a novel therapeutic agent in phase 3 development by Nihon Pharmaceutical Co., Ltd.
At a glance
| Generic name | NPB-01 |
|---|---|
| Also known as | immunoglobulin, Intravenous immunoglobulin |
| Sponsor | Nihon Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited publicly available information exists regarding NPB-01's specific mechanism of action. As a phase 3 candidate from Nihon Pharmaceutical, it represents an investigational compound under active clinical evaluation, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis (PHASE3)
- Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome (PHASE3)
- Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (PHASE2)
- Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. (PHASE3)
- Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (PHASE3)
- Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (PHASE3)
- Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids (PHASE3)
- Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPB-01 CI brief — competitive landscape report
- NPB-01 updates RSS · CI watch RSS
- Nihon Pharmaceutical Co., Ltd portfolio CI